國立虎尾科技大學 |

Antibody-Drug Conjugates = The 21st Century Magic Bullets for Cancer /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Antibody-Drug Conjugates/ edited by Jeffrey Wang, Wei-Chiang Shen, Jennica L. Zaro.
Reminder of title:	The 21st Century Magic Bullets for Cancer /
other author:	Wang, Jeffrey.
Description:	X, 252 p. 59 illus., 32 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Pharmaceutical technology. -
Online resource:	https://doi.org/10.1007/978-3-319-13081-1
ISBN:	9783319130811

Antibody-Drug Conjugates = The 21st Century Magic Bullets for Cancer /
Antibody-Drug ConjugatesThe 21st Century Magic Bullets for Cancer /[electronic resource] :edited by Jeffrey Wang, Wei-Chiang Shen, Jennica L. Zaro. - 1st ed. 2015. - X, 252 p. 59 illus., 32 illus. in color.online resource. - AAPS Advances in the Pharmaceutical Sciences Series,172210-7371 ;. - AAPS Advances in the Pharmaceutical Sciences Series,20.

1 Antibody-Drug Conjugates: A Historical Review -- 2 Payloads of Antibody-Drug Conjugates -- 3 Selecting an Optimal Antibody for Antibody-Drug Conjugate Therapy -- 4 Linker Design for Antibody-Drug Conjugates -- 5 Formulation Development for Antibody-Drug Conjugates -- 6 Bioanalytical Assay for Characterization of Antibody Drug Conjugates -- 7 Pharmacokinetics/Pharmacodynamics and Disposition of Antibody-Drug Conjugates -- 8 Regulatory Considerations -- 9 Major ADC Companies, Current Clinical Trials, Recent Patents Issued and Patent Applications, and Cost Analysis of Drug Therapy -- 10 Mylotarg: Revisiting its Clinical Potential Post-Withdrawal -- 11 ADCETRIS: A Regulatory Case Study of a New Generation Antibody Drug Conjugate -- 12 Ado-Trastuzumab Emtansine -- 13 The Antibody-Drug Conjugate Glembatumumab Vedotin (CDX-011) and its Use in Treatment of Breast Cancer -- 14 Summary and Future Directions.

This authoritative volume provides a holistic picture of antibody-drug conjugates (ADCs). Fourteen comprehensive chapters are divided into six sections including an introduction to ADCs, the ADC construct, development issues, landscape, IP and pharmacoeconomics, case studies, and the future of the field. The book examines everything from the selection of the antibody, the drug, and the linker to a discussion of developmental issues such as formulations, bio-analysis, pharmacokinetic-pharmacodynamic relationships, and toxicological and regulatory challenges. It also explores pharmacoecomonics and intellectual properties, including recently issued patents and the cost analysis of drug therapy. Case studies are presented for the three ADCs that have received FDA approval: gemtuzumab ozogamicin (Mylotarg®), Brentuximab vedotin (Adcetris®), and ado-trastuzumab emtansine (Kadcyla®), as well as an ADC in late-stage clinical trials, glembatumumab vedotin (CDX-011). Finally, the volume presents a perspective by the editors on the future directions of ADC development and clinical applications. Antibody-Drug Conjugates is a practical and systematic resource for scientists, professors, and students interested in expanding their knowledge of cutting-edge research in this exciting field.

ISBN: 9783319130811

Standard No.: 10.1007/978-3-319-13081-1doiSubjects--Topical Terms:

557391
Pharmaceutical technology.

LC Class. No.: RS380

Dewey Class. No.: 615.19

Antibody-Drug Conjugates = The 21st Century Magic Bullets for Cancer /
LDR:03737nam a22004215i 4500 001 965875
003 DE-He213
005 20200706201612.0
007 cr nn 008mamaa
008 201211s2015 gw | s |||| 0|eng d
020 $a 9783319130811 $9 978-3-319-13081-1
024 7 $a 10.1007/978-3-319-13081-1 $2 doi
035 $a 978-3-319-13081-1
050 4 $a RS380
050 4 $a RS190-210
072 7 $a TDCW $2 bicssc
072 7 $a MED072000 $2 bisacsh
072 7 $a TDC $2 thema
082 0 4 $a 615.19 $2 23
245 1 0 $a Antibody-Drug Conjugates $h [electronic resource] : $b The 21st Century Magic Bullets for Cancer / $c edited by Jeffrey Wang, Wei-Chiang Shen, Jennica L. Zaro.
250 $a 1st ed. 2015.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2015.
300 $a X, 252 p. 59 illus., 32 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a AAPS Advances in the Pharmaceutical Sciences Series, $x 2210-7371 ; $v 17
505 0 $a 1 Antibody-Drug Conjugates: A Historical Review -- 2 Payloads of Antibody-Drug Conjugates -- 3 Selecting an Optimal Antibody for Antibody-Drug Conjugate Therapy -- 4 Linker Design for Antibody-Drug Conjugates -- 5 Formulation Development for Antibody-Drug Conjugates -- 6 Bioanalytical Assay for Characterization of Antibody Drug Conjugates -- 7 Pharmacokinetics/Pharmacodynamics and Disposition of Antibody-Drug Conjugates -- 8 Regulatory Considerations -- 9 Major ADC Companies, Current Clinical Trials, Recent Patents Issued and Patent Applications, and Cost Analysis of Drug Therapy -- 10 Mylotarg: Revisiting its Clinical Potential Post-Withdrawal -- 11 ADCETRIS: A Regulatory Case Study of a New Generation Antibody Drug Conjugate -- 12 Ado-Trastuzumab Emtansine -- 13 The Antibody-Drug Conjugate Glembatumumab Vedotin (CDX-011) and its Use in Treatment of Breast Cancer -- 14 Summary and Future Directions.
520 $a This authoritative volume provides a holistic picture of antibody-drug conjugates (ADCs). Fourteen comprehensive chapters are divided into six sections including an introduction to ADCs, the ADC construct, development issues, landscape, IP and pharmacoeconomics, case studies, and the future of the field. The book examines everything from the selection of the antibody, the drug, and the linker to a discussion of developmental issues such as formulations, bio-analysis, pharmacokinetic-pharmacodynamic relationships, and toxicological and regulatory challenges. It also explores pharmacoecomonics and intellectual properties, including recently issued patents and the cost analysis of drug therapy. Case studies are presented for the three ADCs that have received FDA approval: gemtuzumab ozogamicin (Mylotarg®), Brentuximab vedotin (Adcetris®), and ado-trastuzumab emtansine (Kadcyla®), as well as an ADC in late-stage clinical trials, glembatumumab vedotin (CDX-011). Finally, the volume presents a perspective by the editors on the future directions of ADC development and clinical applications. Antibody-Drug Conjugates is a practical and systematic resource for scientists, professors, and students interested in expanding their knowledge of cutting-edge research in this exciting field.
650 0 $a Pharmaceutical technology. $3 557391
650 1 4 $a Pharmaceutical Sciences/Technology. $3 768561
700 1 $a Wang, Jeffrey. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1261530
700 1 $a Shen, Wei-Chiang. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1261531
700 1 $a Zaro, Jennica L. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1261532
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319130828
776 0 8 $i Printed edition: $z 9783319130804
776 0 8 $i Printed edition: $z 9783319376691
830 0 $a AAPS Advances in the Pharmaceutical Sciences Series, $x 2210-7371 ; $v 20 $3 1255084
856 4 0 $u https://doi.org/10.1007/978-3-319-13081-1
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)